Celgene’s Otezla® (apremilast) receives European marketing authorisation

Celgene UK announced that the European Commission has licenced Otezla®, the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (2) For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). Alone or in combination with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Dermatology Rheumatology Patient care chronic plaque psoriasis DMARD Latest News PDE4 inhibitor psoriatic arthritis PUVA Source Type: news

Related Links:

Conclusions: The obtained data indicate that TNF-α, TNFR1, and TNFR2 may be useful markers of the efficacy of anti-TNF therapy, thus complementing clinical parameters. PMID: 32489364 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
The monoclonal interleukin-17A antagonist has three other indications: ankylosing spondylitis in adults, psoriatic arthritis in adults, and plaque psoriasis in adults and children age 6 and older.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news
Abstract Psoriatic arthritis (PsA) is one of the major extra skin manifestations of psoriasis and will develop in 20-30% of patients with psoriasis1 Alternative medicines, mainly herbal products, have been commonly used by patients for the treatment of psoriasis and there have been some studies into their efficacy, but most cases of PsA still require systemic therapy2. PMID: 32482648 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile. PMID: 32479641 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Authors: Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W Abstract Introduction: Fatigue is an important and underrated symptom of many chronic diseases. Aim: The evaluation of incidence and severity of fatigue as well as the influence of selected factors on fatigue in patients with psoriasis and psoriatic arthritis (PsA). Material and methods: The study included 60 patients with PsA, 58 patients with psoriasis and 61 persons in the control group aged 35-70 years. Assessment of fatigue was conducted using a fatigue subscale from the FACIT-F questionnaire. Severity of skin lesions and arthritis was d...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Conclusions: Interleukin-6 may be an indicator of inflammatory activity in psoriasis. Moreover, IL-6 may be related to lipid abnormalities in patients with this disease. PMID: 32467682 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
PSORIATIC arthritis is a long-term condition that may result in deformed joints. The auto-immune condition can stem from the skin condition psoriasis. Here's everything you need to know.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Genome-wide association studies have demonstrated associations between susceptibility to psoriasis and single nucleotide polymorphisms (SNPs). Part of the genetic susceptibility can be explained by the established susceptibility locus in the human leukocyte antigen complex on chromosome 6p21.3, as well as polymorphisms at the interleukin 12B (IL-12B), IL-23A, IL-23 receptor (IL-23R), tumor necrosis factor-a induced protein 3 (TNFAIP3), and TNIP1 (TNFAIP3 interacting protein 1) loci [1 –5]. Investigating susceptibility loci in patients with psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) may help to determine w...
Source: Journal of Dermatological Science - Category: Dermatology Authors: Tags: Letter to the Editor Source Type: research
Conclusions The pharmacological treatment of psoriasis was in accordance with the recommendations of the clinical practice guidelines, but the high proportion of potentially inappropriate prescriptions makes it necessary to promote educational and pharmacovigilance strategies that improve the formulation habits of the physicians involved in the treatment of these patients.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Purpose of review To give an overview of the recently published trials relating to IL-23/IL-17 pathway in spondyloarthritis (SpA). Recent findings Recent studies in psoriasis confirmed the efficacy of targeting the IL-23/IL-17 pathway, with emerging evidence from head-to-head studies suggesting functional hierarchy of these inhibitors. In psoriatic arthritis (PsA), recent studies have indicated the efficacy of inhibiting IL-23p19, in addition to IL-23p40 and IL-17A, albeit all with lower hurdle results than those seen in psoriasis. The first head-to-head study of an IL-17A and tumour necrosis factor inhibitor in PsA h...
Source: Current Opinion in Rheumatology - Category: Rheumatology Tags: SPONDYLOARTHROPATHIES: Edited by Joerg Ermann Source Type: research
More News: Arthritis | Clinical Trials | Dermatology | Drugs & Pharmacology | Marketing | Methotrexate | Psoriasis | Psoriatic Arthritis | Restasis | Rheumatology | Skin